Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Raysum, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 59%, Oct-Dec Ordinary Profit Turns to Loss
8890 Raysum Co., Ltd. 【J-GAAP】
Earnings ReportRaysum Co., Ltd. <8890> [TSE Std] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending September 2025 (April to December) significantly dropped 59.3% from the same period last year to 4.4 billion yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit/loss turned to a loss of 0.2 billion yen (compared to a profit of 1.39 billion yen in the same period last year). The operating profit margin sharply declined from 13.6% in the same period last year to 1.4%.
Note: Due to a change in the fiscal year ending September 2025 (18-month fiscal year), comparisons with the same period in the previous year are not provided since there is no corresponding period.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2022 | 23,361 | 2,889 | 2,685 | 1,872 | 58.8 | 20.9 | Feb 10, 2023 | J-GAAP |
Apr - Dec, 2023 | 53,250 | 11,597 | 10,838 | 7,047 | 249.8 | 49.5 | Feb 9, 2024 | J-GAAP |
Apr - Dec, 2024 | 55,853 | 5,582 | 4,406 | 3,450 | 120.1 | ー | Feb 13, 2025 | J-GAAP |
YoY | +4.9% | -51.9% | -59.3% | -51.0% | -51.9% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 55,437 | 13,193 | 12,438 | 5,301 | 187.1 | 175 | May 10, 2024 | J-GAAP |
Oct - Sep, 2024 Guidance | ー | ー | ー | ー | - | 0 | Dec 20, 2024 | J-GAAP |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 67,906 | 14,371 | 12,851 | 8,376 | 269.7 | 55 | May 12, 2023 | J-GAAP |
Mar, 2024 | 94,265 | 22,824 | 21,878 | 11,513 | 406.3 | 175 | May 10, 2024 | J-GAAP |
Sep, 2025 Guidance | ー | ー | ー | ー | - | 0 | Dec 20, 2024 | J-GAAP |
YoY | - | - | - | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 14,422 | 1,966 | 1,398 | 835 | 29.6 | 13.6 | Feb 9, 2024 | J-GAAP |
Jan - Mar, 2024 | 41,015 | 11,227 | 11,040 | 4,466 | 157.6 | 27.4 | May 10, 2024 | J-GAAP |
Apr - Jun, 2024 | 15,615 | 1,437 | 1,335 | 885 | 30.8 | 9.2 | Aug 9, 2024 | J-GAAP |
Jul - Sep, 2024 | 32,547 | 4,041 | 3,274 | 2,440 | 85.0 | 12.4 | Nov 8, 2024 | J-GAAP |
Oct - Dec, 2024 | 7,691 | 104 | -203 | 125 | 4.4 | 1.4 | Feb 13, 2025 | J-GAAP |
YoY | -46.7% | -94.7% | - | -85.0% | -85.3% |
Related Articles
SENKO, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 11%, Oct-Dec Ordinary Profit Increases by 13%
StemCell Institute, Oct-Dec (3Q) Ordinary Profit Decreases by 27%
PORT, Apr-Dec (Cumulative 3Q) Net Income Increases by 35%, Oct-Dec Net Income Increases by 98%
Grandy House, Oct-Dec (3Q) Ordinary Profit Increases by 2.1 times
GINZA YAMAGATAYA, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Decreases by 36%
CHANGE Holdings, Oct-Dec (3Q) Net Income Increases by 61%
Innovation Holdings, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 42%, Oct-Dec Ordinary Profit Increases by 90%
KLab, Last Fiscal Year's Ordinary Profit Loss Widens, Current period performance is undisclosed.
TABIKOBO, Oct-Dec (2Q) Ordinary Profit Loss Narrows
TAKARA BIO, The Current Fiscal Year Ordinary Profit Revised Downward to an Unexpected 12% Decrease